Charles Schwab Investment Management Inc. Grows Stock Position in LifeStance Health Group, Inc. $LFST

Key Points

• Charles Schwab Investment Management Inc. increased its stake in LifeStance Health Group by 4.4%, owning 1,162,136 shares worth approximately $7.74 million after purchasing an additional 48,637 shares.
• LifeStance Health Group reported revenues of $345.31 million in its latest quarter, exceeding analysts' expectations, with a 10.6% increase compared to the previous year.
• Recent analyst reports indicate a consensus rating of "Moderate Buy" for LifeStance, with an average price target set at $8.50, reflecting positive sentiment towards the company's future prospects.

Charles Schwab Investment Management Inc. raised its position in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 4.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,162,136 shares of the company's stock after purchasing an additional 48,637 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.30% of LifeStance Health Group worth $7,740,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Parcion Private Wealth LLC purchased a new stake in shares of LifeStance Health Group during the 1st quarter valued at about $15,670,000. Janus Henderson Group PLC boosted its position in LifeStance Health Group by 51.4% during the 4th quarter. Janus Henderson Group PLC now owns 59,500 shares of the company's stock valued at $439,000 after purchasing an additional 20,200 shares during the period. Northern Trust Corp boosted its position in LifeStance Health Group by 11.7% during the 4th quarter. Northern Trust Corp now owns 1,591,776 shares of the company's stock valued at $11,731,000 after purchasing an additional 166,731 shares during the period. Victory Capital Management Inc. boosted its position in LifeStance Health Group by 2,599.0% during the 1st quarter. Victory Capital Management Inc. now owns 370,598 shares of the company's stock valued at $2,468,000 after purchasing an additional 356,867 shares during the period. Finally, First Trust Advisors LP acquired a new position in LifeStance Health Group during the 4th quarter valued at approximately $4,535,000. 85.50% of the stock is currently owned by hedge funds and other institutional investors.

LifeStance Health Group Stock Performance

LFST opened at $5.40 on Wednesday. LifeStance Health Group, Inc. has a 52-week low of $3.74 and a 52-week high of $8.61. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.48 and a current ratio of 1.48. The company has a market cap of $2.10 billion, a PE ratio of -108.00 and a beta of 1.13. The stock has a 50-day moving average of $4.69 and a 200-day moving average of $5.96.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.02. The business had revenue of $345.31 million during the quarter, compared to analysts' expectations of $345.05 million. LifeStance Health Group had a negative return on equity of 1.11% and a negative net margin of 1.23%.The firm's revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.06) EPS. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts forecast that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LFST has been the subject of a number of analyst reports. BTIG Research initiated coverage on LifeStance Health Group in a research report on Friday, July 25th. They set a "buy" rating and a $8.00 price target for the company. Wall Street Zen raised LifeStance Health Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, UBS Group boosted their target price on LifeStance Health Group from $8.50 to $9.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, LifeStance Health Group presently has a consensus rating of "Moderate Buy" and an average price target of $8.50.

Insider Buying and Selling

In other news, major shareholder Summit Partners L. P sold 8,407,643 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.07, for a total value of $42,626,750.01. Following the completion of the transaction, the insider directly owned 33,524,715 shares of the company's stock, valued at approximately $169,970,305.05. This represents a 20.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Darren M. Black sold 8,407,643 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.07, for a total value of $42,626,750.01. Following the sale, the director owned 33,524,715 shares in the company, valued at approximately $169,970,305.05. This trade represents a 20.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 20,423,643 shares of company stock valued at $103,561,790. 6.60% of the stock is currently owned by corporate insiders.

LifeStance Health Group Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.